@article{Kerr_S-2022_89764,
title = {COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2:Cohort and test-negative study of 5.4 million individuals in Scotland},
author = {Kerr, S. and Vasileiou, E. and Robertson, C. and Sheikh, A.},
month = {jul},
year = {2022},
abstract = {Background: In July 2021, a new variant of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) in the Delta lineage was detected in the United Kingdom (UK), named AY.4.2 or "Delta plus". By October 2021, the AY.4.2 variant accounted for approximately 10-11% of cases in the UK. AY.4.2 was designated as a variant under investigation by the UK Health and Security Agency on 20 October 2021. This study aimed to investigate vaccine effectiveness (VE) against symptomatic COVID-19 (Coronavirus disease 2019) infection and COVID-19 hospitalisation/death for the AY.4.2 variant.},
issue = {12 },
journal = {Journal of Global Health},
publisher = {International Society of Global Health},
url = {https://doi.org/10.7189/jogh.12.05025},
}
